Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26762018 | 0.84 | PRNP (0.46) | ALDH1A1PRNPMAPTNPSR1RXFP1 | |
| SCHEMBL26762031 | 0.83 | PDE10A (0.33) | ALDH1A1MAPTPDE2APDE10ABACE1 | |
| SCHEMBL26762032 | 0.81 | CRHR1 (0.33) | ALDH1A1PRNPMAPTNPSR1RXFP1 | |
| SCHEMBL26762014 | 0.77 | RXRA (0.33) | — | |
| SCHEMBL26579174 | 0.77 | CA12 (0.33) | ALDH1A1PRNPMAPTNPSR1RXFP1 | |
| SCHEMBL25113804 | 0.75 | CCR1 (0.40) | PDE2APDE10A | |
| SCHEMBL26762022 | 0.66 | ALDH1A1 (0.36) | ALDH1A1PRNPMAPTNPSR1RXFP1 | |
| SCHEMBL26762030 | 0.64 | KMO (0.32) | — | |
| SCHEMBL14239582 | 0.63 | LMNA (0.48) | ALDH1A1 | |
| SCHEMBL25409520 | 0.63 | MBOAT4 (0.38) | ALDH1A1MAPTPDE2APDE10AMBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | ALDH1A1 2152/4885PRNP 267/4885MAPT 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.